WRN was considered as a cancer therapeutic target in hypopharyngeal carcinomas, which have the worst prognosis among head and neck squamous cell carcinomas (HNSCC) with a rapidly rising incidence [43]. The gene discussed is WRN; the disease is head and neck squamous cell carcinoma.